Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 5, 2004, Pages 455-461

  Schwertfeger, Eckhard ^a   Klein, Thomas ^b   Vonend, Oliver ^b   Oberhauser, Vitus ^b   Stegbauer, Johannes ^b   Rump, Lars Christian ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Autonomic nervous system; Heart failure; Parasympathetic; Presynaptic; Sympathetic

Indexed keywords

ADENOSINE TRIPHOSPHATE; MESSENGER RNA; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NORADRENALIN; PURINE P2 RECEPTOR; TETRODOTOXIN;

ACETYLCHOLINE RELEASE; ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; ADULT; AGED; ARTICLE; CHOLINERGIC TRANSMISSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRIC FIELD; ELECTROSTIMULATION; FEMALE; HEART ATRIUM; HEART ATRIUM APPENDAGE; HEART FAILURE; HORMONE ACTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRESSURE CHAMBER; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; AGED; AGED, 80 AND OVER; ARGININE; ATRIAL APPENDAGE; BENZAZEPINES; ELECTRIC STIMULATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; PRESYNAPTIC TERMINALS; RECEPTORS, NEUROPEPTIDE Y; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASODILATOR AGENTS;

EID: 2442707598     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0930-9     Document Type: Article

References (49)

1. Azevedo ER, Parker JD (1999) Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Circulation 100:274-279
2. Bald M, Gerigk M, Rascher W (1997) Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 30:23-27
3. Bodin P, Burnstock G (2001) Purinergic signalling: ATP release. Neurochem Res 26:959-969
4. Brodde OE, Konschak U, Becker K, Ruter F, Poller U, Jakubetz J, Radke J, Zerkowski HR (1998) Cardiac muscarinic receptors decrease with age. In vitro and in vivo studies. J Clin Invest 101:471-478
5. Burger AJ, Aronson D (2001) Activity of the neurohormonal system and its relationship to autonomic abnormalities in decompensated heart failure. J Card Fail 7:122-128
6. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823
7. Curtis BM, O'Keefe JH Jr (2002) Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc 77:45-54
8. 1 receptor antagonist: a review of its pharmacological properties. Regul Pept 65:71-77
9. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K (1999) BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol 384:R3-R5
10. Grassi G, Seravalle G, Bertinieri G, Mancia G (2003) Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. Acta Physiol Scand 177:399-404
11. Gu J, Polak JM, Adrian TE, Allen JM, Tatemoto K, Bloom SR (1983) Neuropeptide tyrosine (NPY) - a major cardiac neuropeptide. Lancet 1:1008-1110
12. Hulting J, Sollevi A, Ullman B, Franco-Cereceda A, Lundberg JM (1990) Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 24:102-108
13. 2 receptors in the postmortem human heart. Peptides 24:255-262
14. 2 prejunctional receptor. Br J Pharmacol 113:479-484
15. Loiacono RE, Story DF (1986) Effect of alpha-adrenoceptor agonists and antagonists on cholinergic transmission in guinea-pig isolated atria. Naunyn-Schmiedebergs Arch Pharmacol 334: 40-47
16. Lundberg JM (1996) Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 48:113-178
17. Lundberg JM, Terenius L, Hokfelt T, Goldstein M (1983) High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man. Neurosci Lett 42:167-172
18. Lundberg JM, Hua XY, Franco-Cereceda A (1984) Effects of neuropeptide Y (NPY) on mechanical activity and neurotransmission in the heart, vas deferens and urinary bladder of the guinea-pig. Acta Physiol Scand 121:325-332
19. Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JH, Ziegler M, Allen RS, Brown MR (1989) Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 86:43-48
20. Manabe N, Foldes FF, Torocsik A, Nagashima H, Goldiner PL, Vizi ES (1991) Presynaptic interaction between vagal and sympathetic innervation in the heart: modulation of acetylcholine and noradrenaline release. J Auton Nerv Syst 32:233-242
21. Marron K, Wharton J, Sheppard MN, Fagan D, Royston D, Kuhn DM, de Leval MR, Whitehead BF, Anderson RH, Polak JM (1995) Distribution, morphology, and neurochemistry of endocardial and epicardial nerve terminal arborizations in the human heart. Circulation 92:2343-2351
22. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998) XVI International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50:143-150
23. Neal M, Cunningham J (1994) Modulation by endogenous ATP of the light-evoked release of ACh from retinal cholinergic neurones. Br J Pharmacol 113:1085-1087
24. Oberhauser V, Vonend O, Rump LC (1999) Neuropeptide Y and ATP interact to control renovascular resistance in the rat. J Am Soc Nephrol 10:1179-1185
25. Oberhauser V, Schwertfeger E, Rutz T, Beyersdorf F, Rump LC (2001) Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes, and age. Circulation 103:1638-1643
26. Odar-Cederlof I, Ericsson F, Theodorsson E, Kjellstrand CM (2003) Neuropeptide-Y and atrial natriuretic peptide as prognostic markers in patients on hemodialysis. ASAIO J 49:74-80
27. Potter E (1987) Presynaptic inhibition of cardiac vagal postganglionic nerves by neuropeptide Y. Neurosci Lett 83:101-106
28. Potter EK (1988) Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther 37:251-273
29. Ren LM, Furukawa Y, Karasawa Y, Murakami M, Takei M, Narita M, Chiba S (1991) Differential inhibition of neuropeptide Y on the chronotropic and inotropic responses to sympathetic and parasympathetic stimulation in the isolated, perfused dog atrium. J Pharmacol Exp Ther 259:38-43
30. Rump LC, Bohmann C, Schaible U, Schollhorn J, Limberger N (1995) Alpha 2C-adrenoceptor-modulated release of noradrenaline in human right atrium. Br J Pharmacol 116:2617-2624
31. Rump LC, Riess M, Schwertfeger E, Michel MC, Bohmann C, Schollmeyer P (1997) Prejunctional neuropeptide Y receptors in human kidney and atrium. J Cardiovasc Pharmacol 29:656-661
32. Rump LC, Amann K, Orth S, Ritz E (2000) Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant 15:1735-1738
33. Schwertfeger E, Wehrens J, Oberhauser V, Katzenwadel A, Rump LC (2001) Contractile effects of tacrolimus in human and rat isolated renal arteries. J Auton Pharmacol 21:205-210
34. Serone AP, Angus JA (1999) Neuropeptide Y is a prejunctional inhibitor of vagal but not sympathetic inotropic responses in guinea-pig isolated left atria. Br J Pharmacol 127:383-390
35. Sesti C, Broekman MJ, Drosopoulos JH, Islam N, Marcus AJ, Levi R (2002) Ectonucleotidase in cardiac sympathetic nerve endings modulates ATP-mediated feedback of norepinephrine release. J Pharmacol Exp Ther 300:605-611
36. Silinsky EM, Ginsborg BL (1983) Inhibition of acetylcholine release from preganglionic frog nerves by ATP but not adenosine. Nature 305:327-328
37. Smith-White MA, Wallace D, Potter EK (1999) Sympathetic-parasympathetic interactions at the heart in the anaesthetised rat. J Auton Nerv Syst 75:171-175
38. 2 receptors at peripheral neuroeffector junctions. Br J Pharmacol 132:861-868
39. Smith-White MA, Herzog H, Potter EK (2002) Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept 103:105-111
40. Smith-White MA, Iismaa TP, Potter EK (2003) Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse. Br J Pharmacol 140:170-178
41. Sosunov EA, Anyukhovsky EP, Rosen MR (1996) Effects of exogenous neuropeptide Y on automaticity of isolated Purkinje fibers and atrium. J Mol Cell Cardiol 28:967-975
42. Takahashi K, Mouri T, Itoi K, Sone M, Ohneda M, Murakami O, Nozuki M, Tachibana Y, Yoshinaga K (1987) Increased plasma immunoreactive neuropeptide Y concentrations in phaeochromocytoma and chronic renal failure. J Hypertens 5:749-753
43. Ullman B, Franco-Cereceda A, Hulting J, Lundberg JM, Sollevi A (1990) Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J Intern Med 228:583-589
44. Ullman B, Pernow J, Lundberg JM, Astrom H, Bergfeldt L (2002) Cardiovascular effects and cardiopulmonary plasma gradients following intravenous infusion of neuropeptide Y in humans: negative dromotropic effect on atrioventricular node conduction. Clin Sci (Lond) 103:535-542
45. Von Kugelgen I, Krumme B, Schaible U, Schollmeyer PJ, Rump LC (1995) Vasoconstrictor responses to the P2x-purinoceptor agonist beta, gamma-methylene-L-ATP in human cutaneous and renal blood vessels. Br J Pharmacol 116:1932-1936
46. Warner MR, Levy MN (1989) Inhibition of cardiac vagal effects by neurally released and exogenous neuropeptide Y. Circ Res 65:1536-1546
47. Wetzel GT, Goldstein D, Brown JH (1985) Acetylcholine release from rat atria can be regulated through an alpha 1-adrenergic receptor. Circ Res 56:763-766
48. Zoccali C, Mallamaci F, Parlongo S, Cutrupi s, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cateliotti A (2002) Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354-1359
49. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS (2003) Neuropeptide Y (NPY), norepinephrine and incident cardiovascular events in end stage renal disease (ESRD). Nephrol Dial Transplant 18:716